Etanercept in Alzheimer disease

With your increased chances of dementia you'll want your doctor and hospital to ensure followup research is done. If not, you don't have a functioning stroke doctor or hospital.  This is a different application of etanercept as compared to Dr. Tobinicks.

Your risk of dementia, has your doctor told you of this?

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

2. Then this study came out and seems to have a range from 17-66%. December 2013.`    

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018 

Your risk of Parkinsons here:

Parkinson’s Disease May Have Link to Stroke March 2017 

The latest here:

Etanercept in Alzheimer disease

A randomized, placebo-controlled, double-blind, phase 2 trial

Joseph Butchart, Laura Brook, Vivienne Hopkins, Jessica Teeling, Ursula Püntener, David Culliford, Richard Sharples, Saif Sharif, Brady McFarlane, Rachel Raybould, Rhodri Thomas, Peter Passmore, V. Hugh Perry, Clive Holmes

First published May 1, 2015, DOI: https://doi.org/10.1212/WNL.0000000000001617

Full PDF

Citation

Permissions

Make Comment

See Comments

Downloads

1615

Add to Cart ($39)

This article has a correction. Please see:

• Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial - December 08, 2015

• Article
• Figures & Data
• Info & Disclosures

Abstract

Objectives: To determine whether the tumor necrosis factor α inhibitor etanercept is well tolerated and obtain preliminary data on its safety in Alzheimer disease dementia.

Methods: In a double-blind study, patients with mild to moderate Alzheimer disease dementia were randomized (1:1) to subcutaneous etanercept (50 mg) once weekly or identical placebo over a 24-week period. Tolerability and safety of this medication was recorded including secondary outcomes of cognition, global function, behavior, and systemic cytokine levels at baseline, 12 weeks, 24 weeks, and following a 4-week washout period. This trial is registered with EudraCT (2009-013400-31) and ClinicalTrials.gov (NCT01068353).

Results: Forty-one participants (mean age 72.4 years; 61% men) were randomized to etanercept (n = 20) or placebo (n = 21). Etanercept was well tolerated; 90% of participants (18/20) completed the study compared with 71% (15/21) in the placebo group. Although infections were more common in the etanercept group, there were no serious adverse events or new safety concerns. While there were some interesting trends that favored etanercept, there were no statistically significant changes in cognition, behavior, or global function.

Conclusions: This study showed that subcutaneous etanercept (50 mg/wk) was well tolerated in this small group of patients with Alzheimer disease dementia, but a larger more heterogeneous group needs to be tested before recommending its use for broader groups of patients.

Classification of evidence: This study shows Class I evidence that weekly subcutaneous etanercept is well tolerated in Alzheimer disease dementia.